Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369327 | 1.00 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1146061 | 0.97 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1146374 | 0.96 | TLR7 (1.00) | TLR7 | |
| SCHEMBL26347160 | 0.91 | TLR7 (0.84) | TLR7 | |
| SCHEMBL1145701 | 0.86 | TLR7 (0.79) | TLR7 | |
| SCHEMBL1145698 | 0.85 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1146490 | 0.85 | TLR7 (1.00) | TLR7 | |
| SCHEMBL1146261 | 0.85 | TLR7 (0.73) | TLR7 | |
| SCHEMBL20756317 | 0.84 | TLR7 (0.73) | TLR7 | |
| SCHEMBL17417198 | 0.84 | TLR7 (1.00) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170022-A1 | COMBINATION DRUG INCLUDING TLR7 AGONIST | Sumitomo Pharma Co., Ltd. (JP) | 2021-06-10 | — | — | US | claimed |
| EP-3730152-A1 | COMBINATION DRUG INCLUDING TLR7 AGONIST | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-10-28 | — | — | EP | claimed |
| CN-111757755-A | Combination comprising a TLR7 agonist | 大日本住友制药株式会社 | 2020-10-09 | — | — | CN | claimed |
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-03 | — | — | US | claimed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | claimed |
| US-12274745-B2 | Conjugate of CAPRIN-1 antibody linked to immune activator for cancer treatment | TORAY INDUSTRIES, INC. (JP) | 2025-04-15 | — | — | US | disclosed |
| US-12226480-B2 | Combination drug including TLR7 agonist | Sumitomo Pharma Co., Ltd. (JP) | 2025-02-18 | — | — | US | disclosed |
| US-12059462-B2 | Composition containing influenza vaccine | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES (JP) | 2024-08-13 | — | — | US | disclosed |
| CN-116115765-A | Combination comprising TLR7 agonists | 住友制药株式会社 | 2023-05-16 | — | — | CN | disclosed |
| US-20210353737-A1 | COMPOSITION CONTAINING INFLUENZA VACCINE | Sumitomo Pharma Co., Ltd. (JP) | 2021-11-18 | — | — | US | disclosed |
| US-20210170022-A1 | COMBINATION DRUG INCLUDING TLR7 AGONIST | Sumitomo Pharma Co., Ltd. (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3827842-A1 | COMPOSITION CONTAINING INFLUENZA VACCINE | JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| WO-2010033074-A1 | USE OF A TLR7 AGONIST FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010033074-A1 | USE OF A TLR7 AGONIST FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-03-25 | — | — | WO | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | NR0B2, NR0B1, BRD7 | TLR7 4/4885 |
| US-12226480-B2 | Combination drug including TLR7 agonist | TLR7, TLR9, CD274 | TLR7 1/4885 |
| US-20210170022-A1 | COMBINATION DRUG INCLUDING TLR7 AGONIST | TLR7, TLR9, CD274 | TLR7 1/4885 |
| US-12059462-B2 | Composition containing influenza vaccine | LY96, CD209, PLA2G12B | TLR7 15/4885 |
| US-20210353737-A1 | COMPOSITION CONTAINING INFLUENZA VACCINE | LY96, CD209, PLA2G12B | TLR7 15/4885 |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | NR0B2, NR0B1, BRD7 | TLR7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.